"Abatacept" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fusion protein immunoconjugate of the extracellular domain of CTLA4 and the Fc domain of human IgG1. It functions as a T-cell co-stimulation blocker that inhibits TNF-ALPHA and prevents the activation of T-LYMPHOCYTES. It is used in the treatment of RHEUMATOID ARTHRITIS.
Descriptor ID |
D000069594
|
MeSH Number(s) |
D12.776.124.790.651.114.580.225 D12.776.377.715.548.114.580.225
|
Concept/Terms |
CTLA-4-Ig- CTLA-4-Ig
- Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin
- Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin
- CTLA4-Ig
- CTLA4-Ig Immunoconjugate
- CTLA4 Ig Immunoconjugate
- Immunoconjugate, CTLA4-Ig
- CTLA4-Fc
|
Below are MeSH descriptors whose meaning is more general than "Abatacept".
Below are MeSH descriptors whose meaning is more specific than "Abatacept".
This graph shows the total number of publications written about "Abatacept" by people in this website by year, and whether "Abatacept" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1997 | 0 | 2 | 2 |
2000 | 0 | 2 | 2 |
2002 | 0 | 3 | 3 |
2003 | 0 | 4 | 4 |
2004 | 0 | 1 | 1 |
2009 | 0 | 2 | 2 |
2017 | 2 | 1 | 3 |
2019 | 0 | 1 | 1 |
2021 | 0 | 1 | 1 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Abatacept" by people in Profiles.
-
Effectiveness of combined plasma cell therapy and costimulation blockade based desensitization regimen in heart transplant candidates. Clin Transplant. 2024 Feb; 38(2):e15249.
-
Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis. J Manag Care Spec Pharm. 2021 01; 27(1):73-83.
-
Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature. J Autoimmun. 2019 07; 101:26-34.
-
Belatacept conversion in an HIV-positive kidney transplant recipient following anti-thymocyte globulin induction. Transpl Infect Dis. 2017 Oct; 19(5).
-
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017 05 08; 5:CD012657.
-
Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis. Sci Transl Med. 2017 02 01; 9(375).
-
A randomized controlled trial to evaluate inhibition of T-cell costimulation in allergen-induced airway inflammation. Am J Respir Crit Care Med. 2013 Mar 01; 187(5):494-501.
-
CTLA4-Ig inhibits allergic airway inflammation by a novel CD28-independent, nitric oxide synthase-dependent mechanism. Eur J Immunol. 2010 Jul; 40(7):1985-94.
-
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ. 2009 Nov 24; 181(11):787-96.
-
Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009 Oct 07; (4):CD007848.